Cambridge Cognition, a leader in developing digital solutions for brain health assessment, has announced the securing of a substantial contract for a pivotal schizophrenia trial with an existing client. This contract, valued at over £600,000 over three years, underscores the company's commitment to advancing cognitive health research.
Key Highlights:
- CANTABTM Cognitive Assessments: Cambridge Cognition will utilize its proprietary CANTABTM digital cognitive assessments, recognized as the gold standard, to evaluate cognitive impairments in schizophrenia patients. These assessments are crucial for measuring deficits in memory, attention, and executive function with high sensitivity.
- Therapeutic Expansion: The contract not only reinforces the company's expertise in cognitive health but also aligns with its strategic goal to broaden its offerings and venture into more therapeutic areas.
- Leadership Insight: Matthew Stork, CEO of Cambridge Cognition, expressed enthusiasm about the ongoing partnership and the potential for future opportunities in schizophrenia drug development, highlighting the value of digital cognitive assessments in this field.
This development is a testament to Cambridge Cognition's innovative approach to cognitive health and its pivotal role in supporting the development of novel pharmaceutical treatments for schizophrenia.